v3.26.1
Note 15 - Segment Information - Summary of Segment Loss (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue $ (28) $ 0
Employee expense (not including stock-based compensation) 5,823 6,212
Development and clinical trial expense 3,227 3,385
Other general and administrative expense(a) [1] 3,666 4,376
Other segment income, net(b) [2] 1,675 (969)
Discontinued operations (73) 0
Segment and condensed consolidated net loss $ (14,290) $ (13,004)
[1] Other general and administrative expense includes consulting and professional services fees, insurance, facilities and other corporate expenses.
[2] Other segment loss (income), net includes gain on sale of future payments, fair value adjustments to warrant liability, interest income and expense, and stock-based compensation expense and marketing support.